Lululemon Stock Hits Extreme Oversold Territory as Analysts Maintain Bullish Forecasts Lululemon stock price has crashed and become highly undervalued. It has also become the most oversold it has been since last year
BlackRock’s CORO ETF Beat Its Benchmark by 6 Points. One Firm Just Bought $55 Million This ETF delivers dynamic exposure to international equities through an active country rotation strategy targeting global market trends.
Want to Retire Abroad? Here Are the Top 3 Spots for Americans. If you've ever dreamed of making a life in a foreign country, here's where you're likely to meet other Americans.
Henry Schein Highlights Dental Momentum, $125M Savings Goal Despite Medical Softness Henry Schein (
NASDAQ:HSIC ) executives said the company is seeing continued momentum in its dental business and remains committed to previously outlined operating improvement targets, while acknowledging softness in medical tied to a weaker respiratory illness season.
Speaking at a Bank of America h
What Lone Peak’s $20 Million Thermon Exit Could Signal After Record Earnings Thermon Group delivers industrial heating solutions worldwide, serving sectors from energy and transit to tech and manufacturing.
KBR Stock Has Fallen 45% This Past Year, but One Investor Just Disclosed a New $24 Million Bet This engineering and technology firm delivers mission-critical solutions to government and industrial clients worldwide.
Is Micron the Next Nvidia? Micron is having an Nvidia moment. That doesn't make it the next Nvidia.
ServisFirst Gets Axed by Champlain — a Minor Position in a Major Drawdown ServisFirst Bancshares delivers commercial and retail banking services across the Southeast with a relationship-driven approach.
Crafting title options within editorial guidelines An ETF Shop Just Made a Beaten-Down Medtech Its Top Holding Artivion delivers advanced cardiovascular and vascular solutions to healthcare providers worldwide through its proprietary medical devices.
US Says China To Buy At Least $17 Billion Worth Agricultural Goods Annually After Trump-Xi Meet President Trump brokers $17B US-China agricultural deal until 2028. Agreement also includes preventing Iran from obtaining nuclear weapons.
Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase Corvus Pharmaceuticals develops immuno-oncology therapies, advancing clinical candidates for cancer and immune-related conditions.
Nio Stock Forms Rare Bullish Pattern As Earnings Loom Nio stock price may be on the cusp of a strong bullish breakout as the company prepares to publish its financial results on Thursday.
Gold Price Nears Death Cross As GLD And IAU ETFs Outflows Jump Gold price may be at risk of further downside as a death cross pattern nears as data shows that the GLD and IAU ETFs are having outflows
Trump Warns Iran There Won't Be Anything Left Of It If It Fails To Move Fast Trump warns Iran to act quickly or face consequences, rejects peace proposal, and prioritizes stopping their nuclear ambitions over domestic concerns.
What Is the Cheapest "Magnificent Seven" Stock? There are two companies investors should consider for bargain values.
Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally This clinical-stage biotech develops innovative retinal disease therapies, with its lead candidate advancing through late-stage trials.
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares Vir Biotechnology develops antibody and RNA-based therapies for infectious diseases, leveraging partnerships and a robust clinical pipeline.
Horizon Quantum Computing Pte. Lays Out Quantum Software Push at Needham Conference Horizon Quantum Computing Pte. (
NASDAQ:HQ ) used its appearance at Needham & Company’s 21st annual Technology, Media, & Consumer Conference to outline its strategy as a newly public quantum software company focused on building infrastructure for developers, hardware providers and end users.
Needham
A China Tech Fund Opens a Biotech Position — Here's What That Actually Signals Legend Biotech develops cell therapies for cancer, with a pipeline spanning hematologic malignancies and solid tumors.
Nvidia Stock Is Poised to Rocket From the Booming Space Economy Nvidia dominates artificial intelligence (AI) on Earth – and it should do the same for AI in space.
With YMM Down 29%, First Beijing Bought 13 Million More Shares Full Truck Alliance is a top digital freight platform in China, connecting shippers and truckers through tech-enabled logistics services.
GDS Was Already Up 47% — Pinpoint Tripled Its Stake Anyway GDS Holdings develops and operates data centers in China, serving major cloud, internet, and financial sector clients.
Trump Closes In On Obama On X — But Guess Who Has Them Both Beat By A Mile The most followed accounts on social media platform X include Elon Musk, politicians and celebrities. Here's the top 10.
Why Plug Power Stock Skyrocketed This Week Plug Power served up some promising news for investors this week.
Snapchat: Don't Rush to Buy This Social Media Stock Snap is unprofitable after almost 15 years and doesn't have the revenue growth rates of an exciting start-up.
M&G Shaved 2.4% of Methanex After a Near-Doubling Methanex supplies methanol worldwide, using integrated operations and its own fleet to serve industrial clients across major global markets.
XRP Price Stagnates As Spot Ripple ETFs Heads For Best Month In 2026 Ripple (CRYPTO: XRP) has gone nowhere this month, continuing a consolidation that began in February.
Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares Tyra Biosciences develops targeted therapies for cancer and rare diseases, leveraging proprietary technology to advance its drug pipeline.
This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million Viridian Therapeutics develops monoclonal antibody therapies targeting serious diseases, with a primary focus on thyroid eye disease.
Where Could Palantir Be in 10 Years? The Bull and Bear Cases. Palantir remains a high-variance AI infrastructure bet where narrative and execution will matter equally over the next decade.
Why Poet Technologies Stock Skyrocketed This Week Poet's new contract announcement powered huge gains for the stock.
This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million This clinical-stage biotech develops oral therapeutics for chronic diseases, with a pipeline centered on metabolic and pulmonary targets.
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases through proprietary TYK2 inhibitors.
TLT ETF Outflows Jump As Top Pro Warns On Soaring US Bond Yields The TLT ETF suffered substantial outflows last week as experts continued to warn about the rising US government bond yields.
CAVA Group Stock Recovery Has Faltered: Will Earnings Spark A Rebound? CAVA Group stock price has sunk into a bear market after falling by over 20% from its highest point this year. Will earnings spark a rebound?
Walmart Stock Hits Key Resistance As Valuation Concerns Creep Up Ahead Of Earnings Walmart stock price hit a crucial resistance, forming a double-top pattern, as valuation concerns emerged ahead of earnings.
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet The Stock Whisper Index looks at five stocks seeing strong interest from Benzinga readers during the week and highlights the catalysts that could be driving the attention.
Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally This clinical-stage biotech develops antibody therapies for severe autoimmune diseases, targeting rare neuromuscular conditions.
Why Would Anyone Buy SPYM Instead of QQQ? Buying the S&P 500 instead of the Qs could help you avoid relying too heavily on tech stocks.
Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More This clinical-stage biotech targets RAS/MAPK pathway cancers with a pipeline of novel small molecule oncology therapies.
